Akums Drugs & Pharmaceuticals Ltd

Akums Drugs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Akums Drugs & Pharmaceuticals Ltd

₹ 473 2.81%
28 Mar - close price
akums.in BSE: 544222 NSE: AKUMS
About

Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.[1]

Key Points

Business Profile[1] Akums Drugs is a Contract Development and Manufacturing Organization (CDMO) manufacturing tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies.

Website BSE NSE
  • Market Cap ₹ 7,448 Cr.
  • Current Price ₹ 473
  • High / Low ₹ 1,176 / 433
  • Stock P/E 97.2
  • Book Value ₹ 142
  • Dividend Yield 0.00 %
  • ROCE -14.3 %
  • ROE -69.3 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Debtor days have improved from 75.7 to 59.1 days.

Cons

  • Stock is trading at 3.33 times its book value
  • Company has a low return on equity of -36.8% over last 3 years.
  • Earnings include an other income of Rs.118 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of Nifty Total Market Nifty MidSmallcap 400 Nifty Smallcap 250 BSE Healthcare BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
316 447 383 298 317 328 337
503 358 351 359 274 285 303
Operating Profit -187 89 32 -61 44 43 34
OPM % -59% 20% 8% -20% 14% 13% 10%
20 4 25 25 26 32 34
Interest 4 5 5 5 6 4 2
Depreciation 7 8 8 9 9 9 11
Profit before tax -178 81 43 -49 54 62 55
Tax % 6% 35% 32% 18% 23% 18% 25%
-190 53 29 -58 42 50 41
EPS in Rs -13.26 3.69 2.05 -4.05 2.84 3.20 2.62
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
683 737 837 1,162 1,287 1,444 1,281
603 697 811 1,524 1,089 1,571 1,221
Operating Profit 80 40 27 -362 198 -127 60
OPM % 12% 5% 3% -31% 15% -9% 5%
58 66 -195 58 -4 75 118
Interest 4 4 1 4 13 18 17
Depreciation 23 25 26 28 30 33 39
Profit before tax 112 76 -195 -335 150 -103 122
Tax % 33% 33% -26% 14% 17% 61%
75 51 -145 -382 125 -165 76
EPS in Rs 636.94 391.05 -1,118.18 -53.37 8.77 -11.56 4.61
Dividend Payout % 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 16%
3 Years: 20%
TTM: 12%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -170%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: -7%
3 Years: -37%
Last Year: -69%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 1 1 1 14 29 29 31
Reserves 841 711 566 171 283 115 2,204
51 36 41 140 188 267 137
153 678 690 1,488 1,395 1,684 327
Total Liabilities 1,046 1,426 1,298 1,814 1,894 2,095 2,699
237 242 244 253 272 317 316
CWIP 0 1 1 1 16 9 18
Investments 4 65 149 141 139 139 139
806 1,118 903 1,419 1,466 1,631 2,225
Total Assets 1,046 1,426 1,298 1,814 1,894 2,095 2,699

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
-22 56 228 94
-242 -100 -298 -202
302 3 95 90
Net Cash Flow 38 -42 25 -18

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 85 88 92 95 73 59
Inventory Days 93 96 67 85 91 68
Days Payable 60 85 63 120 82 69
Cash Conversion Cycle 118 99 96 61 82 58
Working Capital Days 103 138 100 37 40 43
ROCE % 10% 8% -71% 74% -14%

Shareholding Pattern

Numbers in percentages

Sep 2024Dec 2024
75.26% 75.26%
7.34% 6.36%
7.53% 6.99%
7.14% 8.64%
2.73% 2.73%
No. of Shareholders 57,53168,410

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

No data available.

DRHP

Credit ratings

Concalls